Syed Zaidi, MD
Gastroenterology · Bismarck, NDNPI 1467486969
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,719 of the $5,536 with a category attached, or 85.2%. 26 manufacturers reported payments, led by AbbVie at 27.8% of the total. Reporting peaked in 2024 at $1,634 and has fallen 66.3% since, to $551 in 2025. Among gastroenterology clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Boston Scientific$869
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$689
- Johnson & Johnson$684
- Takeda Pharmaceuticals U.S.A., Inc.$650
- Pfizer$191
- plus $916 from 20 others
What the payments were for
- Travel & lodging$5069%
- Food & beverage$4,71985%
- Education$3116%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 114 | $1,537 |
| Boston Scientific | 4 | $869 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 58 | $689 |
| Johnson & Johnson(2 entities) | 24 | $684 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $650 |
| Pfizer | 18 | $191 |
| Bristol Myers Squibb | 9 | $138 |
| Ardelyx, Inc. | 1 | $102 |
| Merck | 6 | $82 |
| UCB, Inc. | 4 | $72 |
| Ipsen Biopharmaceuticals, Inc | 4 | $69 |
| Daiichi Sankyo Inc. | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Intercept Pharmaceuticals, Inc. | 3 | $43 |
| Sanofi | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 3 | $39 |
| Gilead | 2 | $38 |
| Amgen | 1 | $30 |
| Madrigal Pharmaceuticals | 1 | $25 |
| QOL Medical, LLC | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Organon | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Sandoz | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXALT Model D$705
- IBSRELA$102
How this compares
$5,536 in reported general payments places this provider in the 95th percentile of 26 gastroenterology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 17 | $451,354 |
| Humira(Cf) PenAdalimumab | 14 | $189,360 |
| LinzessLinaclotide | 49 | $30,982 |
| Pantoprazole Sodium | 764 | $8,750 |
| VoqueznaVonoprazan Fumarate | 11 | $8,365 |
| Mesalamine | 16 | $5,504 |
| Colestipol Hcl | 85 | $5,401 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 178 | $3,513 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 14 | $1,980 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 101 | $1,865 |
| Entecavir | 12 | $1,824 |
| Budesonide DrBudesonide | 14 | $1,629 |
| Mesalamine ErMesalamine | 13 | $1,355 |
| Ursodiol | 11 | $1,294 |
| Esomeprazole Magnesium | 29 | $848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $684 | $451,35417 claims |
| AbbVieLinzess | $1,537 | $30,98249 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $39 | $8,36511 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $689 | $1,98014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 gastroenterology providers in North Dakota.
Other gastroenterology in Bismarck
- Mark BrewsterBismarck$4K
- Douglas RentonBismarck$2K
- Mustafa KathawalaBismarck$2K
- Makda BsratBismarck$2K
- Kevin KarlsBismarck$2K
- Nicholas BattistaBismarck$1K
- Tawhid GaziBismarck$572
- Yeshitila MengeshaBismarck$532
- Elida VothBismarck$31
- Arezoo TaheriFargo$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.